AU2173400A - Method for administering agents to the central nervous system - Google Patents
Method for administering agents to the central nervous systemInfo
- Publication number
- AU2173400A AU2173400A AU21734/00A AU2173400A AU2173400A AU 2173400 A AU2173400 A AU 2173400A AU 21734/00 A AU21734/00 A AU 21734/00A AU 2173400 A AU2173400 A AU 2173400A AU 2173400 A AU2173400 A AU 2173400A
- Authority
- AU
- Australia
- Prior art keywords
- nervous system
- central nervous
- administering agents
- agents
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 210000003928 nasal cavity Anatomy 0.000 abstract 1
- 210000003901 trigeminal nerve Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20853998A | 1998-12-09 | 1998-12-09 | |
| US09208539 | 1998-12-09 | ||
| PCT/US1999/029335 WO2000033814A2 (en) | 1998-12-09 | 1999-12-09 | Method for administering agents to the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2173400A true AU2173400A (en) | 2000-06-26 |
Family
ID=22774961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU21734/00A Abandoned AU2173400A (en) | 1998-12-09 | 1999-12-09 | Method for administering agents to the central nervous system |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1135105B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2002531490A (cg-RX-API-DMAC10.html) |
| AT (1) | ATE289800T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2173400A (cg-RX-API-DMAC10.html) |
| DE (1) | DE69923998T2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2000033814A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1305294B1 (it) | 1999-01-29 | 2001-05-04 | Alessandro Lambiase | Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari. |
| EP1602378A1 (en) * | 1999-12-09 | 2005-12-07 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
| WO2001041782A2 (en) * | 1999-12-09 | 2001-06-14 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
| CA2597525A1 (en) * | 2005-02-17 | 2006-08-24 | Senju Pharmaceutical Co., Ltd. | Solid ophthalmic drug for external use |
| US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
| ITRM20050447A1 (it) * | 2005-08-19 | 2007-02-20 | Anabasis S R L | Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson. |
| JP5276982B2 (ja) | 2005-08-26 | 2013-08-28 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | オキシトシンの投与による頭痛の処置のための方法 |
| WO2007127163A2 (en) | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
| KR101760139B1 (ko) * | 2007-06-29 | 2017-07-31 | 클라렌슈 피티와이 리미티드 | 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물 |
| WO2011072091A1 (en) | 2009-12-09 | 2011-06-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
| US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
| US8987199B2 (en) | 2011-06-15 | 2015-03-24 | Nerve Access, Inc. | Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders |
| JP2016523835A (ja) | 2013-05-15 | 2016-08-12 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入 |
| RS59490B1 (sr) | 2014-11-21 | 2019-12-31 | Biohaven Therapeutics Ltd | Sublingvalna formulacija riluzola |
| WO2016085787A1 (en) * | 2014-11-25 | 2016-06-02 | Corning Incorporated | Cell culture media extending materials and methods |
| PL3242676T3 (pl) | 2015-01-07 | 2024-07-15 | Tonix Pharma Limited | Preparaty oksytocyny zawierające magnez i sposoby ich stosowania |
| US11207461B2 (en) | 2015-07-30 | 2021-12-28 | Anoop U. R | Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier |
| WO2017017543A1 (en) * | 2015-07-30 | 2017-02-02 | U R Anoop | Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier |
| HRP20250215T1 (hr) | 2016-04-12 | 2025-06-20 | Tonix Pharma Limited | Formulacije oksitocina koje sadrže magnezij i postupci upotrebe |
| US11253612B2 (en) | 2016-04-15 | 2022-02-22 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type II |
| EP3509585B1 (en) * | 2016-09-07 | 2023-11-01 | Glia, LLC | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
| EP3684938A1 (en) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0200757B1 (en) * | 1984-10-19 | 1992-03-11 | Chiron Corporation | Promotion of wound healing with human epidermal growth factor prepared from recombinant dna |
| US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| CA2167104A1 (en) * | 1995-01-17 | 1996-07-18 | Joerg G.D. Birkmayer | Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration |
| JP3191038B2 (ja) * | 1996-06-26 | 2001-07-23 | 輝夫 西田 | 眼科用医薬組成物 |
| US5840736A (en) * | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| IT1289608B1 (it) * | 1997-02-05 | 1998-10-15 | Angelini Ricerche Spa | Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale |
-
1999
- 1999-12-09 EP EP99966114A patent/EP1135105B1/en not_active Expired - Lifetime
- 1999-12-09 AU AU21734/00A patent/AU2173400A/en not_active Abandoned
- 1999-12-09 AT AT99966114T patent/ATE289800T1/de not_active IP Right Cessation
- 1999-12-09 JP JP2000586308A patent/JP2002531490A/ja active Pending
- 1999-12-09 WO PCT/US1999/029335 patent/WO2000033814A2/en not_active Ceased
- 1999-12-09 DE DE69923998T patent/DE69923998T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000033814A2 (en) | 2000-06-15 |
| ATE289800T1 (de) | 2005-03-15 |
| JP2002531490A (ja) | 2002-09-24 |
| EP1135105B1 (en) | 2005-03-02 |
| WO2000033814A3 (en) | 2000-11-30 |
| DE69923998T2 (de) | 2006-04-27 |
| DE69923998D1 (de) | 2005-04-07 |
| EP1135105A2 (en) | 2001-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000033814A3 (en) | Method for administering agents to the central nervous system | |
| AU2049500A (en) | Administration of neurotrophic agents to the central nervous system | |
| UA41906C2 (uk) | Спосіб лікування неврологічних порушень, викликаних травмами | |
| GB2380414A (en) | Stimulation method for the sphenopalatine ganglia,sphenopalatine nerve,or vidian nerve for treatment of medical conditions | |
| AU3402295A (en) | Methods and means for drug administration | |
| AU2339792A (en) | Treatment of respiratory disorders by nerve stimulation | |
| CA2114014A1 (en) | Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine | |
| PL398445A1 (pl) | Kompozycje farmaceutyczne zawierające dekstrometorfan i chininę do leczenia zaburzeń neurologicznych | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| PL316313A1 (en) | Naphtyloamides as agents acting on a central nerve system | |
| IL148071A0 (en) | Method for treatment of symptoms of central nervous system disorders | |
| DE69331605D1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| WO2001041782A3 (en) | Method for administering a cytokine to the central nervous system and the lymphatic system | |
| MY135838A (en) | Methods for the treatment of mental disorders | |
| EP1085862A4 (en) | METHODS OF TREATING AUTOIMMUNE DISEASES | |
| MY124786A (en) | Bis-arylsulfones | |
| BG106065A (en) | Method for the treatment of neurological or neuropsychiatric disorders | |
| GB9212308D0 (en) | Therapeutic compositions | |
| WO2000051590A3 (en) | Neuropharmacological treatment of sleep-related breathing disorders | |
| AP9901473A0 (en) | Use of benzopyranols to treat neurological disorders. | |
| BG105962A (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders | |
| MXPA02005667A (es) | Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos. | |
| MXPA03001160A (es) | Metodo para tratar desordenes neurodegenerativos de la retina y cabeza de nervio optico. | |
| WO2002005801A3 (en) | Compositions containing diacyltartaric salts of (e)-metanicotine | |
| IL130586A0 (en) | IL6RIL6 chimera for the treatment of demyelinating diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |